$4.91
+6.28%Price chart
Apr 17Apr 22Apr 27Apr 30May 5May 8May 13May 18
Key dataMay 18, 2026
Open$5.32
From 52W high−72.72%
Volume441020.00
Market cap$3.55M
P/E (TTM)—
P/S (TTM)70.7x
Div yield—
Key dataMay 18, 2026
Open
$5.32
From 52W high
−72.72%
Volume
441020.00
Market cap
$3.55M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.0x
P/E (TTM)
—
RSI (14)
45.2
MomentumView details →
1D Return
+6.28%
YTD Return
−34.55%
SummaryUpdated Jun 1, 2026
Predictive Oncology Inc. (NASDAQ:POAI) is a knowledge-driven biotechnology company founded in 2002 and headquartered in Eagan, Minnesota. Originally incorporated as Precision Therapeutics Inc., the company rebranded to its current name in June 2019 to better reflect its focus on artificial intelligence-driven cancer research. The company has evolved from a traditional medical device manufacturer into a science-driven organization that leverages artificial intelligence and machine learning to advance personalized cancer therapies and drug discovery processes.
Similar companies
Latest newsMore news →
DataMeds AI, Inc. issued 636,328 shares of common stock and a $1,363,672 convertible promissory note to Axe Compute Inc. in a private placement valued at $1.5 million.4d agoAxe Compute and Duos Technologies announced agreements to add up to 55 MW of AI data center capacity across multiple U.S. locations.34d agoAxe Compute Inc. reported financial results for the second quarter ended June 30, 2026, with revenue growing more than 90x sequentially from Q1 2026 and more than $2.8 billion in new contracts signed during the quarter, bringing 2026 signed contracted value to over $3 billion.37d ago